Experience in Production of 68Ga-DOTA-NOC for Clinical Use Under an Expanded Access IND
dc.contributor.author | Green, Mark A. | |
dc.contributor.author | Mathias, Carla J. | |
dc.contributor.author | Fletcher, James W. | |
dc.contributor.department | Department of Radiology and Imaging Sciences, IU School of Medicine | en_US |
dc.date.accessioned | 2017-03-31T19:34:22Z | |
dc.date.available | 2017-03-31T19:34:22Z | |
dc.date.issued | 2016-10 | |
dc.description.abstract | [68Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert & Ziegler (EZAG) 68Ge/68Ga-generator (with fractionated elution), or the SiO2-based ITG 68Ge/68Ga-generator. In both cases, [68Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the68Ga generator eluate, using readily-implemented manual synthesis procedures. [68Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4%. Administered 68Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2 µg (n=47) and 23.9±5.7 µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, 68Ge breakthrough in the final product averaged 2.7×10−7% and 5.4×10−5% using the EZAG and ITG generators, respectively. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Green, M. A., Mathias, C. J., & Fletcher, J. W. (2016). Experience in production of 68Ga-DOTA-NOC for clinical use under an Expanded Access IND. Applied Radiation and Isotopes, 116, 63–68. https://doi.org/10.1016/j.apradiso.2016.07.010 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/12166 | |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.isversionof | 10.1016/j.apradiso.2016.07.010 | en_US |
dc.relation.journal | Applied Radiation and Isotopes | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | Author | en_US |
dc.subject | expanded access IND | en_US |
dc.subject | neuroendrocrine tumors | en_US |
dc.subject | somatostatin receptor | en_US |
dc.title | Experience in Production of 68Ga-DOTA-NOC for Clinical Use Under an Expanded Access IND | en_US |
dc.type | Article | en_US |